GlassScriptPhysician profile
Darren D Brennan
NPI 1710904172
$478,465.00
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $201K · 2020: $154K · 2021: $119K · 2022: $4,500.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $358,405.00 | 2019-2021 | |
| Pfizer INC. | $112,650.00 | 2019-2021 | |
| Janssen Research & Development, LLC | $4,500.00 | 2022 | |
| Acerta Pharma LLC | $2,910.00 | 2019 |
19 companies reported research payments only; those appear in the research section below.
Research and ownership
$164,758.58 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$372,310.12 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.